Explore

Shift from Animal Models to New Approach Methodologies in Preclinical Research

Shift from Animal Models to New Approach Methodologies in Preclinical Research

Shift from Animal Models to New Approach Methodologies in Preclinical Research

Advocacy for Cruelty-Free Medicines Gains Momentum in the U.S.

Advocacy for Cruelty-Free Medicines Gains Momentum in the U.S.

Animal Wellness Action and the Center for a Humane Economy are advocating for a shift towards cruelty-free medicines in the U.S. This movement follows the successful campaign to rescue beagles from Ridglan Farms, a breeding facility involved in the laboratory animal pipeline. The campaign aims to transform the drug development ecosystem by encouraging pharmaceutical companies to adopt human-relevant preclinical discovery programs, moving away from traditional animal testing. Recent legislative changes, such as the FDA Modernization Act 3.0, have begun to dismantle regulatory mandates for animal testing, opening the door for more humane and reliable drug development methods.

Ohio State Researchers Discover Noncoding RNA with Potential ATPase Function

Ohio State Researchers Discover Noncoding RNA with Potential ATPase Function

Researchers at The Ohio State University have identified a noncoding RNA derived from human cells that can bind to ATP, a molecule essential for cellular energy. This discovery challenges the traditional view that only proteins, specifically ATPases, can facilitate ATP's energy release. The team, led by Peixuan Guo, is exploring the RNA's function, hoping it mimics ATPase activity, which could lead to new therapeutic applications. This research builds on previous findings of viral RNA binding to ATP and aims to develop RNA-based nanomaterials for medical use.

FDA Advances AI in Clinical Trial Design to Enhance Drug Development

FDA Advances AI in Clinical Trial Design to Enhance Drug Development

FDA Advances AI in Clinical Trial Design to Enhance Drug Development

Sanofi Halts Atopic Dermatitis Trials Following Efficacy Concerns

Sanofi Halts Atopic Dermatitis Trials Following Efficacy Concerns

Sanofi Halts Atopic Dermatitis Trials Following Efficacy Concerns

Enveda's ENV-294 Shows Promising Results in Atopic Dermatitis Trial

Enveda's ENV-294 Shows Promising Results in Atopic Dermatitis Trial

Enveda Biosciences has announced positive results from its Phase 1b trial of ENV-294, a potential first-in-class oral therapy for moderate-to-severe atopic dermatitis. The trial, presented at the American Academy of Dermatology Innovation Academy, showed that patients experienced significant improvements in their Eczema Area and Severity Index (EASI) scores, with a mean reduction of 68% by Day 28 and 85% by Day 42. The study involved nine patients, all of whom achieved EASI-50 by Day 42, with 78% reaching EASI-75 and 56% achieving EASI-90. The drug was generally well-tolerated, with only one reported headache as an adverse event.

Rigel Pharmaceuticals Appoints Alison Hannah as Chief Medical Officer

Rigel Pharmaceuticals Appoints Alison Hannah as Chief Medical Officer

Rigel Pharmaceuticals Appoints Alison Hannah as Chief Medical Officer

AstraZeneca's Global Pharmaceutical Impact and Strategic Developments

AstraZeneca's Global Pharmaceutical Impact and Strategic Developments

AstraZeneca's Global Pharmaceutical Impact and Strategic Developments

FDA Advisory Committee Votes on Peptide BPC-157 Amid Safety Concerns

FDA Advisory Committee Votes on Peptide BPC-157 Amid Safety Concerns

The FDA's Pharmacy Compounding Advisory Committee (PCAC) has voted 8-6, with one abstention, to add the peptide BPC-157 to a drug compounding list, moving it closer to legal availability with a prescription. This decision is part of a broader review of seven peptides, which have gained popularity for purported health benefits like muscle building and metabolism improvement. Despite the vote, the decision is non-binding and requires FDA approval. The committee's consideration of an atypical regulatory pathway for these peptides has sparked debate, as there is limited human clinical trial data supporting their safety and effectiveness. Health Secretary Robert F. Kennedy Jr. has promoted peptide use, but the process has faced criticism over potential conflicts of interest among committee members.

Sanofi Halts Atopic Dermatitis Trials for Kymab Acquisition Due to Efficacy Concerns

Sanofi Halts Atopic Dermatitis Trials for Kymab Acquisition Due to Efficacy Concerns

Sanofi Halts Atopic Dermatitis Trials for Kymab Acquisition Due to Efficacy Concerns

Bioengineering Advances: Hybrid Living Models Enhance Vascular Disease Research

Bioengineering Advances: Hybrid Living Models Enhance Vascular Disease Research

Recent developments in bioengineering have introduced hybrid living models that integrate both the bath and bioink as active components. These models are particularly promising for creating perfusable tubes with stiffness gradients and spatial heterogeneity of cell types, which are crucial for reconstructing vascularized tissue microenvironments. This approach allows for the exploration of interactions between arteries and their surrounding tissue environment, providing insights into various vascular diseases. The models are designed to mimic the structural and functional aspects of human vessels, enabling researchers to study the etiology of vascular diseases more effectively. The focus is on developing disease-aligned toolchains, including standardized bioinks and validated perfusion protocols, to deliver actionable physiological insights.

Analysis-AstraZeneca 'magic' faces rare test after trial failure, share slide

Analysis-AstraZeneca 'magic' faces rare test after trial failure, share slide

By Maggie Fick LONDON, July 24 (Reuters) - AstraZeneca's long-time CEO Pascal Soriot has rarely put a foot wrong. The company's shares have more that quadrupled in price during his 14-year tenure, soaring above the wider FTSE 100 index and main British rival GSK.